Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Entrada Therapeutics, Inc. (TRDA) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement, by and between Entrada Therapeutics, Inc. and Cowen and Company, LLC",
"Legal Opinion of Goodwin Procter LLP"
08/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Entrada Therapeutics Appoints Gina Chapman to its Board of Directors BOSTON, Aug. 10, 2023 -- Entrada Therapeutics, Inc. , a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle -therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. “Gina is a seasoned leader with more than thirty years of experience driving the commercial and operational growth of numerous biopharmaceutical companies,” said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. “With a proven track record of advancing therapeutics into the market, Gin..."
08/08/2023 8-K Quarterly results
Docs: "Entrada Therapeutics Reports Second Quarter 2023 Financial Results"
08/01/2023 8-K Quarterly results
06/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/10/2023 8-K Quarterly results
Docs: "Entrada Therapeutics Reports First Quarter 2023 Financial Results - $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 - - Cash runway into the second half of 2025 -"
04/04/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors"
03/06/2023 8-K Quarterly results
Docs: "Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results"
02/09/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1"
01/09/2023 8-K Other Events  Interactive Data
Docs: "Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable"
12/19/2022 8-K Quarterly results
12/08/2022 8-K Quarterly results
11/07/2022 8-K Quarterly results
Docs: "Entrada Therapeutics Reports Third Quarter 2022 Financial Results On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 for the potential treatment of patients with Duchenne muscular dystrophy who are exon 44 skipping amenable in the fourth quarter of 2022"
08/11/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/22/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Lease Agreement, between IDB 17-19 Drydock Limited Partnership and Entrada Therapeutics, Inc"
03/15/2022 8-K Quarterly results
12/09/2021 8-K Quarterly results
11/02/2021 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Fourth Amended and Restated Certificate of Incorporation of Entrada Therapeutics, Inc",
"Amended and Restated Bylaws of Entrada Therapeutics, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy